AI, proteomics, and smarter development reshape pharma R&D

This cluster explores how next-generation tools are transforming drug discovery and development, from AI-driven design and predictive models for early oral drugs to integrating high-throughput and spatial proteomics for better target identification. It also examines operational advances—such as low-drama CDMO collaboration strategies, tackling the costly Phase II jobs-to-be-done gap, and the technologies honored in the 2026 Scientists’ Choice Awards. The passing of Purdue pioneer Phil Low adds historical perspective, highlighting how past breakthroughs underpin today’s Pharma 4.0 era.